Kaipu Biotech plans to set up a new investment company with 20 million yuan, and the industry will cooperate to dig deep into the "Dawan District" dividend.
On December 11th, Kaipu Bio Holding Co., Ltd. Kaipu Medical Inspection intends to set up Guangzhou Kaipu Medical Investment Co., Ltd. with its own capital of 20 million yuan (the final name is subject to the approval of the industrial and commercial registration authority). The announcement revealed that the proposed address is Guangzhou City, Guangdong Province, and its business scope includes investment consulting services. Founded in 2003, Cap Bio is currently the leading enterprise in the diagnosis of nucleic acid molecules in China. Based on the diversion hybrid technology platform with independent intellectual property rights and the application of the international fluorescent PCR detection technology platform, the research and development products cover infectious disease detection and genetic disease detection. Two major areas. In terms of third-party testing centers, Capco Biotech relies on Cap's medical testing to gradually expand the downstream market and create an industry service model of its own “instrument + reagent + service†chain. In December 2017, Kaipu Bio said that it plans to increase the capital of Kaipu Medical Inspection, and plans to set up 25 “Cape Inspection Institutes†in major provinces and cities nationwide to engage in medical testing of nucleic acid molecules. In addition to the newly established investment company with 20 million yuan of self-owned funds, in November this year, Kaipu Medical Inspection and 8 companies including Guangzhou Mintou jointly initiated the establishment of Guangzhou Precision Medicine Sample Bank Investment Operation Center (limited partnership). ). The total fundraising size of the partnership is 400 million yuan, of which the investment amount of the Cape Medical Examination as a limited partner is 50 million yuan. According to the original plan, the Guangzhou Precision Medicine Sample Bank Investment Operation Center (Limited Partnership) will cooperate with the Guangzhou Municipal Government to invest in high-quality enterprises with unique competitive advantages in the biomedical field to create a company with scientific and industrial value. Dawan District Biomedical Sample Library. This is also reflected in the layout of the newly established investment company. Further analysis of the announcement pointed out that the new Guangzhou Kaipu Medical Investment Co., Ltd. is conducive to the development of Kaipu's biological business growth channels. After the establishment of the new company, it will cooperate with other partners of Capco Biotech to carry out foreign investment, and through the effective integration of resources, carry out business such as construction of medical association, hospital pathology, inspection and other departments. In recent years, with the promotion of the “Guangdong, Hong Kong, Macao and Dawan District†strategy, the dividend in the biomedical field has been further stimulated. It can be found that in addition to maintaining its own advantages in the field of original nucleic acid molecular diagnostics, Capum's biology is also constantly deployed around the upstream and downstream industrial chains. The newly established investment company will be an important step for Kaipu Bio in the ecological closed loop. Referring to the previous pre-judgment of Daan's genetic polishing industry investment model, Yiouda Health believes that in the long run, the layout of Kaipu Bio-industry will be gradually developed under the guise of the “Guangdong, Hong Kong, Macao and Dawan District†strategy. To provide a continuous impetus for future development. Zhejiang Industrial Group Co., Ltd. , https://www.xingyeseafood.com